Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study
Authors
Keywords
-
Journal
Journal for ImmunoTherapy of Cancer
Volume 7, Issue 1, Pages -
Publisher
BMJ
Online
2019-12-03
DOI
10.1186/s40425-019-0821-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Paraneoplastic syndromes: Definitions, classification, pathophysiology and principles of treatment
- (2019) Kristin Henry SEMINARS IN DIAGNOSTIC PATHOLOGY
- Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors
- (2019) Francesc Graus et al. Nature Reviews Clinical Oncology
- Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease
- (2018) François-Xavier Danlos et al. EUROPEAN JOURNAL OF CANCER
- Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
- (2018) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis
- (2017) Sébastien Le Burel et al. EUROPEAN JOURNAL OF CANCER
- Paraneoplastic syndromes associated with gynecological cancers: A systematic review
- (2017) Mathieu Viau et al. GYNECOLOGIC ONCOLOGY
- Autoimmune limbic encephalitis with anti-contactin-associated protein-like 2 antibody secondary to pembrolizumab therapy
- (2017) Michael P Brown et al. JOURNAL OF NEUROIMMUNOLOGY
- iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
- (2017) Lesley Seymour et al. LANCET ONCOLOGY
- Anti‐Hu‐Associated Autoimmune Limbic Encephalitis in a Patient with PD‐1 Inhibitor‐Responsive Myxoid Chondrosarcoma
- (2017) Kyriakos P. Papadopoulos et al. ONCOLOGIST
- Immune-related adverse events with immune checkpoint blockade: a comprehensive review
- (2016) J.M. Michot et al. EUROPEAN JOURNAL OF CANCER
- Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
- (2016) Scott J Antonia et al. LANCET ONCOLOGY
- Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper
- (2015) S. Champiat et al. ANNALS OF ONCOLOGY
- Paraneoplastic syndromes in rheumatology
- (2014) Bernhard Manger et al. Nature Reviews Rheumatology
- Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: A systematic review and meta-analysis
- (2011) Ernesto Trallero-Araguás et al. ARTHRITIS AND RHEUMATISM
- Paraneoplastic Neurologic Syndrome in the PNS Euronetwork Database
- (2010) Bruno Giometto ARCHIVES OF NEUROLOGY
- Paraneoplastic Syndromes: An Approach to Diagnosis and Treatment
- (2010) Lorraine C. Pelosof et al. MAYO CLINIC PROCEEDINGS
- Factors Associated With Underlying Malignancy in a Retrospective Cohort of 121 Patients With Dermatomyositis
- (2009) Laurence Fardet et al. MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started